Faculty profile

Kevin Imrie

ResearcherCritical Care MedicineUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Kevin Imrie

Researcher

Critical Care Medicine

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
No publications since 2021.
Principal investigator on 2 research grants (2 CIHR), most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

129

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Patient Safety Post-Graduate Medical Education Rct Resident Wellbeing Assessment Metrics Clinical Practice Models Competency-Based Training Internal Medicine

Latest papers

Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review
Pathology Research and Practice · 2021
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
Leukemia & lymphoma · 2019
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
British journal of haematology · 2019

All 17 publications

Latest funding

The Intensive Care Unit Resident Scheduling (InCURS) trial: A cluster RCT of 16 and 24 hour schedules in Canadian ICUs
CIHR · 2018 · Principal investigator
$3,048,525
InCURS: Intensive Care Unit Residents Scheduling Study
CIHR · 2016 · Co-investigator
$100,000
A scoping review of training and clinical models for invasive bedside procedures performed by internists
CIHR · 2013 · Principal investigator
$49,585

All 3 grants and awards

17 publications.

Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review

Morgan S, Tremblay-LeMay R, Lipa JE, Sur M, Delabie J, Imrie K, Crump M, Snell LJ, Ghorab Z

Pathology Research and Practice202127 citations

DOI: 10.1016/j.prp.2021.153589

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE

Leukemia & lymphoma2019

DOI: 10.1080/10428194.2018.1515937 PMID: 30301414

Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.

Smyth L, Buckstein R, Pennell N, Weerasinghe R, Cheung MC, Imrie K, Spaner D, Piliotis E, Chodirker L, Reis M, Ghorab Z, Zhang L, Boudreau V, Miliken A, Berinstein N

British journal of haematology2019

DOI: 10.1111/bjh.15118 PMID: 29380359

Eosinophils in the skin-a red herring masking lymphoma: a case series.

Jaque A, Mereniuk A, Sade S, Lansang P, Imrie K, Shear NH

SAGE open medical case reports2018

DOI: 10.1177/2050313x18773127 PMID: 29899986

Core Competencies or a Competent Core? A Scoping Review and Realist Synthesis of Invasive Bedside Procedural Skills Training in Internal Medicine.

Brydges R, Stroud L, Wong BM, Holmboe ES, Imrie K, Hatala R

Academic medicine : journal of the Association of American Medical Colleges2017

DOI: 10.1097/acm.0000000000001726 PMID: 28489618

What do I do? Developing a competency inventory for postgraduate (residency) program directors.

Lieff SJ, Zaretsky A, Bandiera G, Imrie K, Spadafora S, Glover Takahashi S

Medical teacher2016

DOI: 10.3109/0142159x.2016.1147532 PMID: 27049589

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study

Buckstein R, Fraser G, Cheung M, Kukreti V, Kuruvilla J, Imrie K, Piliotis E, Pond G, Windsor J, Ghorab Z

Clinical Lymphoma, Myeloma and Leukemia201617 citations

DOI: 10.1016/j.clml.2015.11.008

A systematic review of the effects of resident duty hour restrictions in surgery: impact on resident wellness, training, and patient outcomes.

Ahmed N, Devitt KS, Keshet I, Spicer J, Imrie K, Feldman L, Cools-Lartigue J, Kayssi A, Lipsman N, Elmi M, Kulkarni AV, Parshuram C, Mainprize T, Warren RJ, Fata P, Gorman MS, Feinberg S, Rutka J

Annals of surgery2014

DOI: 10.1097/sla.0000000000000595 PMID: 24662409

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.

Mozessohn L, Cheung MC, Crump M, Buckstein R, Berinstein N, Imrie K, Kuruvilla J, Piliotis E, Kukreti V

Leukemia & lymphoma2014

DOI: 10.3109/10428194.2014.885513 PMID: 24450580

Survival of patients with transformed lymphoma in the rituximab era.

Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R

Annals of hematology2014

DOI: 10.1007/s00277-013-1991-y PMID: 24414374

Something wrong or missing on this profile? Suggest a correction

Kevin Imrie

Research

Latest papers

Latest funding

Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study&#x2020;.

Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-&#x3b1; induces prolonged clinical and molecular remissions in patients with follicular lymphoma.

Eosinophils in the skin-a red herring masking lymphoma: a case series.

Core Competencies or a Competent Core? A Scoping Review and Realist Synthesis of Invasive Bedside Procedural Skills Training in Internal Medicine.

What do I do? Developing a competency inventory for postgraduate (residency) program directors.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study

A systematic review of the effects of resident duty hour restrictions in surgery: impact on resident wellness, training, and patient outcomes.

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.

Survival of patients with transformed lymphoma in the rituximab era.

The Intensive Care Unit Resident Scheduling (InCURS) trial: A cluster RCT of 16 and 24 hour schedules in Canadian ICUs

InCURS: Intensive Care Unit Residents Scheduling Study

A scoping review of training and clinical models for invasive bedside procedures performed by internists

Frequent collaborators

David Spaner

John Kuruvilla

Ralph Meyer

Najma Ahmed

Irwin Ronald Walker

Liane Feldman

Ahmed Kayssi

Sudeep Shivakumar

Lisa Chodirker

Lee Mozessohn

Nir Lipsman

Tony Reiman

Jonathan Spicer

Jan Delabie

Arun Seth

Ari Zaretsky

James Rutka

Susan Glover Takahashi

Tony Reiman

Mitchell Levine

Nadine Shehata

Gregory Pond

Ryan Brydges

Monalisa Sur

Mark Norman Levine

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.